Both Th1 and Th17 Are Immunopathogenic but Differ in Other Key Biological Activities

Catherine A. Cox, Guangpu Shi, Hongen Yin, Barbara P. Vistica, Eric F. Wawrousek, Chi-Chao Chan and Igal Gery

_J Immunol_ 2008; 180:7414-7422; doi: 10.4049/jimmunol.180.11.7414

http://www.jimmunol.org/content/180/11/7414

References
This article cites 53 articles, 28 of which you can access for free at: http://www.jimmunol.org/content/180/11/7414.full#ref-list-1

Subscriptions
Information about subscribing to _The Journal of Immunology_ is online at: http://jimmunol.org/subscriptions

Permissions
Submit copyright permission requests at: http://www.aai.org/ji/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/cgi/alerts/etoc
Both Th1 and Th17 Are Immunopathogenic but Differ in Other Key Biological Activities

Catherine A. Cox,‡* Guangpu Shi,‡* Hongen Yin,‡ Barbara P. Vistica,* Eric F. Wawrousek, ‡ Chi-Chao Chan,* and Igal Gery*†

The role of Th17 lymphocytes in immunopathogenic processes has been well established, but little is known about their basic cell features. In this study, we compared polarized Th1 and Th17 for key biological activities related to pathogenicity and trafficking. Th1 and Th17 lineages were derived from TCR-transgenic CD4 murine cells specific against hen egg lysozyme. When adoptively transferred into mice expressing hen egg lysozyme in their eyes, both Th1 and Th17 induced ocular inflammation but with slight differences in histological pathology. PCR analysis revealed selective expression of IFN-γ or IL-17 in eyes of Th1 or Th17 recipients, respectively. Additionally, Th1 and Th17 were found to differ in three other key activities: 1) Th1 cells were inferior to Th1 cells in their capacity to trigger massive lymphoid expansion and splenomegaly; 2) the proportion of Th1 cells among infiltrating cells in inflamed recipient eyes declined rapidly, becoming a minority by day 7, whereas Th17 cells remained in the majority throughout this period; and 3) remarkable differences were noted between Th1 and Th17 cells in their expression of certain surface markers. In particular, reactivated Th1 expressed higher levels of CD49d and αβ (mucosal homing) in vitro and higher levels of CXCR3 (Th1 trafficking) in vivo. Reactivated Th17, however, expressed higher levels of αβ (epithelial tissue homing) and CD38 (activation, maturation and trafficking) in vitro, but in vivo Th17 expressed higher levels of αβ and CCR6 (lymphocyte trafficking). These data reveal that Th1 and Th17 cells differ in several key biological activities influencing migration and pathogenic behavior during inflammatory disease. The Journal of Immunology, 2008, 180: 7414–7422.

Materials and Methods

Mice

“HEL-Tg” mice expressing membrane-associated HEL under control of the αA-crystallin promoter and on an FVB/N background were generated as described (19). HEL-specific TCR-Tg mice (designated “3A9”) on a B10.BR background, were a gift from M. Davis (Stanford University, Stanford, CA). Tg mice from each line were mated to produce (FVB/N × B10.BR) F1 hybrids that express HEL, HEL-specific TCR, or both or neither transgene (“wild type” (WT)). The F1 hybrids containing the best of our knowledge, this approach for defining the basic features of Th17 cells, including their pathogenic potential and other biological capacities, has not yet been reported. The present study used this approach to compare polarized populations of Th1 and Th17 for their capacity to adoptively transfer immune-mediated ocular inflammation as well as for other key biological activities.

In our experimental system, T cells from TCR-Tg mice specific against hen egg lysozyme (HEL) have been shown to induce ocular inflammation when adoptively transferred into Tg mice expressing HEL in their eyes (14, 17, 18). We obtained polarized lineages of Th1 and Th17 by repeated incubation of naive CD4 cells from TCR-Tg mice with HEL and mixtures of cytokines and Abs known to skew activation toward either a Th1 or a Th17 phenotype. Both Th lineages were found to be immunopathogenic, with slight differences in patterns of pathological changes induced in recipient eyes. In addition, the two lineages differed remarkably in their capacity to stimulate massive lymphoid expansion in recipient mice, in their profile of chemokine secretion, as well as in their expression of several surface markers in vitro and in vivo. Interestingly, remarkable differences were also noted between the two subsets in their kinetics of intraocular invasion and host cell recruitment.

Received for publication July 5, 2007. Accepted for publication March 31, 2008.
Cytokines, Abs, and Ag

IL-6 and TGF-β were provided by R&D Systems, IL-1α was obtained from PeproTech. IL-2 was from Midwest Medical, anti-INF-γ (clone R4-6A2) was from Harlan Bioproducts for Science, anti-IL-4 (clone 1B11) was from National Cancer Institute-Frederick Biological Resources Branch Procurement and Requisition (Frederick, MD), and both IL-12 and HEL were purchased from Sigma-Aldrich. The following reagents were purchased from BD Biosciences: anti-CD4 PerCP, allophycocyanin, or PE-Cy7 (clone RM4-5), anti-CD16/CD32 (clone 2.4G2), anti-CD38 PE (clone 90), anti-CD45RB PE (clone 16A), anti-CD49d PE (clone 9C10 (MFR4.B)), anti-CD4 PerCP, allophycocyanin, or PE-Cy7 purchased from Sigma-Aldrich. The following reagents were purchased from E. Unanue (Washington University, St. Louis, MO), was conjugated with 2 μg/ml HEL and irradiated (30 Gy) syngeneic WT naive splenocytes serving as APCs (5 × 10^7/ml) (14) in either Th1-polarizing conditions (10 ng/ml IL-12 and 10 μg/ml anti-IL-4) or Th17-polarizing conditions (3 ng/ml TGF-β, 10 ng/ml IL-6, 5 μg/ml anti-IL-4, 10 μg/ml anti-IL-12, and 20 μg/ml anti-IFN-γ). Polarized cells were expanded in the presence of 40 IU/ml IL-2 for an additional 4 days with daily 1-ml medium changes. Finally, cells were harvested and replated for 3 days of reactivation with 2 μg/ml HEL, WT naive irradiated APCs, and either 10 ng/ml IL-12 plus 40 IU/ml IL-2 for Th1 cells or a cytokine-Ab mixture for Th17 cells (10 ng/ml IL-23, 3 ng/ml TGF-β, 10 ng/ml IL-6, 5 μg/ml IL-1α, 40 IU/ml IL-12, and 20 μg/ml anti-IFN-γ). For cell lines designated “expanded IL,” reactivated cells were reincubated in the presence of 40 IU of IL-2 for an additional 11 days with daily 1-ml medium changes. Reactivated Th2 cell lines were generated as detailed elsewhere (14).

Surface Ag analysis

Cells were stained according to standard protocol with a set of conjugated Abs including 1G12 FITC, CD4 PerCP, or allophycocyanin, a surface Ag of choice conjugated with PE (see above), plus 7-amino-actinomycin D to exclude dead cells. Stained cells were analyzed by FACSCalibur flow cytometry and analyzed with FlowJo 6.4.7. Before all staining, anti-CD16/CD32 was used to block FcRs.

Cytokine analysis

Release of cytokines and chemokines into the culture medium was measured on day 3 of reactivation by the SearchLight system (Pierce Biotechnology).

For intracellular cytokine analysis, reactivated cultures were stimulated with 20 ng/ml PMA and 1 μM ionomycin (Sigma-Aldrich) plus Golgi-Stop (BD Biosciences) for 5 h. Stimulated cells were processed on a Lympholyte-M gradient (Cedarlane) for dead cell removal. Cells were then stained for surface CD4 FITC, washed, and then fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences). Finally, cells were stained for intracellular IFN-γ, allophycocyanin/IL-17 PE, and analyzed by FACSCalibur flow cytometry.

For mRNA analysis, TRIzol reagent (Invitrogen) was used to extract total RNA from reactivated cultures or from whole eyes of recipient mice after perfusion with PBS on day 5 postadoptive transfer. Total RNA was incubated with DNase (Promega), reverse transcribed into cDNA using oligo primers and SuperScript II RT (Invitrogen), and then analyzed by real-time RT-PCR on an ABI Prism 7700 with TaqMan primer/probe sets for IFN-γ and IL-17 (Applied Biosystems).

Adaptive transfer studies

Th1 or Th17 cells were harvested on day 3 of reactivation, resuspended in RPMI 1640, and injected via the tail vein into naive HEL-Tg or WT mice.

For HEL-Tg recipients, eyes were collected at different time points. To perform mRNA analysis (described above), eyes were collected on day 7 and processed by conventional H&E methods. For isolation of inflammatory cells, eyes were collected on days 4 and 7 (see below).

For WT recipients, spleens were collected on day 4 postadoptive transfer, weighed, and splenocyte numbers were determined. Blood was processed on an Isolymph gradient (Budenheim/Gallard-Schlesinger) for mononuclear leukocyte (MNL) isolation and counting.

Isolation of cells from eyes

On days 4 and 7 postadoptive transfer, eyes of Th1 or Th17 recipients were collected, dissected, and digested in RPMI 1640 medium containing 10% FCS, 1 mg/ml collagenase D (Roche), and deoxyribonuclease I (Sigma-Aldrich) for 2 h. Following digestion, eye tissue was mechanically disrupted and filtered through a 40-μm cell strainer. Isolated cells were washed twice in RPMI 1640 and prepared for flow cytometric analysis.

Statistical analyses

Student’s t test was used for statistical analyses. Significance was defined as p < 0.05.

Results

Polarized Th1 and Th17 cells selectively produce either IFN-γ or IL-17

To generate Th1 and Th17 lineages, TCR-Tg CD4 cells specific against HEL were polarized and reactivated using mixtures of cytokines and Abs known to drive polarization toward a Th1 or Th17 phenotype (see Materials and Methods). We examined each lineage for phenotypic purity by measuring the release into culture medium (Fig. 1A), intracellular production (Fig. 1B), and mRNA transcript levels (Fig. 1C) of the two signature cytokines, IFN-γ and IL-17. All assays revealed high levels of polarity, with selective expression of IFN-γ by Th1 or that of IL-17 by Th17.

Secretion of chemokines and cytokines by Th cell lines

Th1 and Th17 cells secrete cytokines and chemokines that affect other cell populations. To collect information on the activity of Th1 and Th17 cells, we measured the levels of several major chemokines from culture supernatants following 3 days of reactivation. To obtain an expanded perspective on this issue, we also examined the secretion pattern of reactivated Th2 cell lines. Table I summarizes a representative experiment; similar secretion profiles were obtained in two other experiments. It is notable that the number of Th1 cells per milliliter at the end of restimulation was considerably lower than that of the other Th populations as a result of their high apoptosis. The collected data identify four chemokines that are secreted at relatively high levels by the tested Th populations, with individual patterns of preference by each of the three Th subsets (Table I). These chemokines include MDC/CCL22, MIP-1α/CCL3, RANTES/CCL5 and TARC/CCL17 (where TARC stands for “thymus- and activation-regulated chemokine”). We also show in Table I the levels of IL-10 secreted by the three cell lines, because the production of IL-10 by Th17 was recently reported to determine the immunopathogenicity of Th17 cell preparations (20). Moderate levels of IL-10 were secreted by Th1 and Th17, whereas Th2 secreted an ~10-fold higher level of this cytokine. Levels of all tested molecules were profoundly lower than those of the signature cytokines.

Both Th1 and Th17 are immunopathogenic, with some differences in the histopathological changes induced by each

To compare Th1 and Th17 cells of our system for their immunopathogenic capacities, we adoptively transferred different numbers of HEL-specific polarized and reactivated Th1 or Th17 cells into groups of mice that express membrane-associated HEL in their eyes (“HEL-Tg” mice). We examined eyes of recipient mice 7 days later for pathological changes that were scored on a 0–9 scale as detailed elsewhere (14, 17). These data are summarized in Fig.
2A; Th1 was found to be more immunopathogenic at lower cell numbers, but similar levels of severity were induced in mice injected with $2 \times 10^6$ cells from both the Th1 and Th17 lineages.

Fig. 2, B–E depict typical changes in the eyes of recipients injected with $1 \times 10^6$ cells of the two lineages. Sections of a naive HEL-Tg mouse, added for comparison, show no signs of inflammation in any ocular tissue. Conversely, both Th1 and Th17 induced inflammation in the anterior and posterior eye segments as well as edema in most tissues, which is apparent when compared with corresponding tissue from the naive control. Interestingly, Th17 differed from Th1 by exhibiting a stronger affinity for the cornea of inflamed eyes; infiltrating cells in Th17 recipient eyes were found to invade into the central, deep corneal stroma (Fig. 2D). Th17 recipient eyes were also noted to have more severe corneal epithelial edema (Fig. 2C). In contrast, Th1 recipient eyes depicted more severe retinal inflammation and folding than Th17 recipient eyes (Fig. 2E).

Selective production of IFN-γ or IL-17 in eyes of Th1 or Th17 recipients

To determine whether adoptively transferred cells maintained lineage specificity, we next examined the expression levels of IFN-γ and IL-17 in inflamed eyes of Th1 and Th17 recipients. We determined expression levels by measuring mRNA transcripts from whole inflamed eyes using quantitative PCR. The data from two experiments, summarized in Fig. 3, show a predominance of IFN-γ in Th1 recipient eyes and a predominance of IL-17 in Th17 recipient eyes. These data confirm the selective expression of either IFN-γ or IL-17 by the Th1 and Th17 lineages, even following adoptive transfer and inflammation in the eye. Of interest was the finding that although IL-17 transcript was essentially absent in the eyes of Th1 recipients, a low level of IFN-γ transcript was expressed in the eyes of Th17 recipients.

Th1 and Th17 differ remarkably in their capacity to stimulate host lymphoid expansion in naive recipients

In a previous communication (18) we showed that polarized, re-activated Th1 cells have the capacity to induce transient splenomegaly when adoptively transferred into naive recipient mice. An increase in spleen size and cellularity peaks on day 4 postadoptive transfer, consisting of a mixed host cell population, then leads to a rapid decrease and return to baseline by day 7. Based on these earlier observations, we compared the spleen size and cell number of Th1 and Th17 recipients on day 4 postadoptive transfer (Fig. 4). In line with our previous data (18), spleens in recipients of $10^6$ Th1 increased in size and cell number to approximately twice the value of control mice. Conversely, significantly smaller changes were noted in spleen size (Figs. 4, A and B) and cell number (Fig. 4C) in Th17 recipients.

In addition, previous adoptive transfer studies of reactivated Th1 showed a sharp increase in circulating MNLs that accompanied changes in the spleen (our unpublished data). We therefore tested peripheral blood from Th1 and Th17 recipients on day 4 postadoptive transfer. Similar to the trends in spleen size and cellularity,

![Graph](image-url)
Th1 recipients showed a substantially greater increase in circulating MNLs than Th17 recipients (Fig. 4D).

Given that T-regulatory cells could have contributed to the inferior capacity of Th17 to stimulate lymphoid expansion, we used flow cytometric analysis to evaluate our cell preparations. CD4\(^+\)CD25\(^+\)Foxp3\(^+\) cells were not detected in any of the Th17 cell suspensions tested (data not shown).

Cultured Th1 and Th17 differ in their expression of surface molecules at two stages in vitro

In view of our observation that Th1 and Th17 can induce distinct changes in the eyes and spleens of recipient mice, we examined two stages of culture for differences in surface molecule expression. We tested the “reactivation” stage just before adoptive transfer and the “expansion II” stage following 11 days of additional incubation with IL-2 (21). Data from a representative experiment are summarized both in graphic form (Fig. 5A) and in flow cytometry plots (Fig. 5B); similar observations were made in two additional experiments. Fig. 5A additionally shows the staining pattern of naive CD4 cells before in vitro activation. As expected, naive cells were negative for a majority of tested surface molecules with the exception of CCR7, CD45RB, and CD62L.

At the reactivation stage, Th1 and Th17 exhibited similar expression levels of the activation markers CD25 and CD69 (22, 23) as well as the chemokine receptor CCR7 (24). Remarkably, however, reactivated Th1 and Th17 showed significantly different expression levels for all other tested markers. The expression level of CD45RB, known to be down-regulated on mature cells (25), was...
lower on Th17 than on Th1. In contrast, Th1 expressed higher levels of the marker CD49d, while down-regulation of the molecule CD62L was more pronounced on Th17. Increased expression of CD49d and decreased expression of CD62L together characterize the ability of T lymphocytes to invade nonlymphoid tissues (18, 26). Expression levels of α4β7 (LPAM-1) and αEβ7 (CD103) were also significantly different; Th1 cells were found to express higher levels of α4β7, an integrin involved in mucosal tissue homing (27), whereas Th17 expressed moderately higher levels of αEβ7, an integrin involved in epithelial tissue homing (28). Additionally, a noticeable difference was found in the expression patterns of CD38, a multifunctional marker for maturation, activation, and trafficking (29, 30), with Th17 expressing high levels and Th1 expressing low levels. Neither Th lineage at this stage of culture expressed measurable levels of the chemokine receptor CXCR3.

Fewer differences between Th1 and Th17 were observed after an extended incubation with IL-2 (i.e., the “expansion II” stage), as compared with reactivated cells. Exceptions included an increase in levels on Th17 of CD49d and α4β7 with a concomitant decrease on Th1, as well as a sharp increase in CXCR3 expression only on Th1. This pattern regarding CXCR3 up-regulation on Th1 is in line with our previous data (21). Of note, Th17 did not up-regulate

![FIGURE 5. Differential surface marker expression on Th1 and Th17 cells in vitro. A, Suspensions of naive CD4 cells, as well as Th1 or Th17 cells at two different stages in vitro, were immunostained with mAbs against major surface markers. Th1 and Th17 cell surface markers were analyzed at the following culture stages: 1) after polarization and reactivation, just before injection into recipient mice (“React”); and 2) after 11 days of additional culture in the presence of IL-2 (“Expand II”). Numbers represent the percentage of positive or “high” positive cells gated on the CD4+G12-7AAD- population. Recorded values were obtained in a representative experiment; similar results were obtained in two additional experiments. B, Flow cytometric plots of a representative experiment showing Th1 and Th17 surface marker expression at the “reactivated” stage.](http://www.jimmunol.org/Downloadedfrom)
CXCR3 but alternatively up-regulated the two other trafficking markers, CD49d and α4β7. As seen with pathological changes in the eye and spleen, this finding emphasizes a distinct difference in the activities of Th1 and Th17 upon exposure to certain environmental stimuli.

A recent publication (31) showed that the chemokine receptor CCR6 is expressed by human Th17 profoundly more than by Th1. Flow cytometric analysis of CD4 cells in our system (Fig. 5) revealed a low level of CCR6 on naive cells, a marginal increase on Th1 following reactivation, and the lowest expression following expansion. In contrast, the level of CCR6 on Th17 increased following reactivation and was further elevated to 40% following expansion II.

Adoptively transferred Th1 and Th17 express different surface molecules in spleens and eyes of recipients

As shown by other groups and our own (21, 32), adoptively transferred Th cells can undergo significant surface molecule changes upon reaching the spleen or after invading target tissue. We therefore compared, in the current study, surface marker expression on Th1 and Th17 from the spleens and eyes of recipient mice. Surface marker analysis was performed on day 4 postadoptive transfer because Th1 invasion of the eye has been shown to peak on day 4 with relatively low levels of host cell recruitment (18, 21). We used a clonotypic Ab specific against the 3A9 Tg TCR, designated “1G12”, to detect donor cells in recipient eyes.

Fig. 6 summarizes data from a representative experiment; similar data were obtained in an additional experiment.

CXCR3 but alternatively up-regulated the two other trafficking markers, CD49d and α4β7. As seen with pathological changes in the eye and spleen, this finding emphasizes a distinct difference in the activities of Th1 and Th17 upon exposure to certain environmental stimuli.

A recent publication (31) showed that the chemokine receptor CCR6 is expressed by human Th17 profoundly more than by Th1. Flow cytometric analysis of CD4 cells in our system (Fig. 5) revealed a low level of CCR6 on naive cells, a marginal increase on Th1 following reactivation, and the lowest expression following expansion. In contrast, the level of CCR6 on Th17 increased following reactivation and was further elevated to >40% following expansion II.

Adoptively transferred Th1 and Th17 express different surface molecules in spleens and eyes of recipients

As shown by other groups and our own (21, 32), adoptively transferred Th cells can undergo significant surface molecule changes upon reaching the spleen or after invading target tissue. We therefore compared, in the current study, surface marker expression on Th1 and Th17 from the spleens and eyes of recipient mice. Surface marker analysis was performed on day 4 postadoptive transfer because Th1 invasion of the eye has been shown to peak on day 4 with relatively low levels of host cell recruitment (18, 21). We used a clonotypic Ab specific against the 3A9 Tg TCR, designated “1G12”, to detect donor cells in recipient eyes.

Fig. 6 summarizes data from a representative experiment; similar data were obtained in an additional experiment. Of particular interest, we found that: 1) unlike the striking difference in culture between Th1 and Th17 (Fig. 5), most surface marker levels in vivo were relatively similar; 2) exceptions to these similarities included a considerably higher level of α4β7 expressed on Th17, both in spleens and eyes of recipients, whereas only Th1 expressed high levels of CXCR3 in recipient spleens; and 3) the activation markers CD25 and CD69, especially the latter, were more highly expressed in recipient eyes compared with recipient spleens. Our in vivo findings further highlight the differences that exist between Th1 and Th17 with regard to their ability to up-regulate distinct trafficking markers. Any surface marker discrepancies between our in vitro and in vivo studies likely result from specific cytokine milieus present in each studied environment.

Th1 and Th17 differ in their kinetic invasion and host cell recruitment in recipient eyes

Because Th1 and Th17 were found to up-regulate distinct trafficking markers in vitro and in vivo, we compared each lineage for its unique capacity to invade and recruit host cells in recipient eyes. It has been shown that a major component of immune-mediated inflammation is the recruitment of nonspecific lymphoid cells to inflamed tissue (18, 33, 34). In this study, we isolated cells from inflamed recipient eyes on days 4 and 7 postadoptive transfer of Th1 or Th17 and then analyzed for proportions of donor and host cell populations. According to previous studies, Th1 recruitment of host cells was expected to reach its peak on day 7 (18, 21).

Flow cytometric analysis of donor and host cell populations, isolated on days 4 and 7 postadoptive transfer revealed a striking difference between the two cell lineages. Data from a representative experiment are shown in Fig. 7A, while Fig. 7B summarizes...
data from this and two other experiments. In line with previous observations (21), the majority of infiltrating cells in Th1 recipient eyes were donor cells (1G12+) on day 4, whereas the majority had shifted to host cells (1G12-) by day 7. In contrast, little change was seen in the ratio between donor and host cells in Th17 recipient eyes from day 4 to day 7; donor cells were the clear majority at both time points in Th17 recipient eyes. These remarkable differences in the kinetics of invasion and host cell recruitment suggest that the basic characteristics of Th1 and Th17 may play a role in establishing disease patterns unique to each lineage.

Discussion
The important role played by Th17 cells in immunopathogenic processes has been well established (1–7), but until now, little had been described concerning their basic mechanism of action or other biological activities. To collect new data about Th17 cells and to compare their activities with those of the well-described Th1 cells, we generated in vitro lineages of both Th1 and Th17 from naive CD4 cells expressing a TCR specific against HEL. We then examined in vitro and in vivo differences between these two lineages. The purity of each lineage was demonstrated by measuring the production of IFN-γ or IL-17, the signature cytokines for the Th1 and Th17 cell types, respectively.

The culture conditions that we used to generate Th1 and Th17 lineages were in line with previously published methods (9). It is important to note, however, that our Th17 lineage was cultured in the presence of IL-2, both at the “expansion” and “reactivation” stages. Recently, IL-2 was reported to have an inhibitory effect on the activation of Th17 cells from a naive state (35). In our study, we detected no difference in IL-17 expression when Th17 cells were cultured with or without IL-2 following the initial polarization step (data not shown), thus indicating that inhibitory effects of IL-2 are likely restricted to an earlier stage of activation. Indeed, we found in another study (G. Shi, C. A. Cox, B. P. Vistica, C. Tan, E. F. Wawrousek, and I. Gery, “Phenotype switching by inflammation-inducing polarized Th17, but not by Th1 cells,” submitted for publication) that adding anti-IL-2 Ab to the early activation mixture (35) increased considerably the proportion of Th17 cells, from 50–60% to 70–80% following routine reactivation.

When transferred into Tg mice expressing HEL in their eyes, both Th1 and Th17 induced ocular inflammation. Some differences were noted, however, in specific pathological features resulting from each lineage, as depicted in Fig. 2. In addition, flow cytometric analysis of infiltrating cell populations in recipient eyes revealed remarkably higher proportions of neutrophils (Gr-1+) in Th17 eyes when compared with Th1 eyes (11.3 vs 3.7%, respectively). In contrast, macrophages (F4/80+) and CD3 cells were observed in similar proportions in both the Th1 group and the Th17 group. Greater accumulation of neutrophils in Th17 recipients is in accord with reports of IL-17 acting as a stimulator of neutrophil mobilization (36, 37) as well as granulopoiesis (3).

It is of interest that unlike the observed pathogenic similarity between our polarized Th1 and Th17 cells, Langrish et al. (6) and Elson et al. (11) found that Th17 cells are by far superior to Th1 cells when tested for their capacity to induce experimental autoimmune encephalomyelitis or colitis, respectively. The discrepancy that exists between our model and the other two models has not yet been elucidated.

The contribution of Th1 and Th17 cells to pathogenic processes of ocular inflammation has been analyzed mostly in eyes with experimental autoimmune uveitis. Both Th1 and Th17 cells were identified in these eyes (38–40), and Yoshimura et al. (38) suggested that the two cell populations are involved at different phases of the inflammatory process. In addition, we analyzed the Th pop-

ulations in mouse eyes in which autoimmune-mediated inflammation was triggered by treatment with TLR ligands, using the system described by Fujimoto et al. (41). In this system, naive 3A9 CD4 cells induce ocular inflammation in HEL-Tg recipients following activation in vivo by TLR ligands. Different ratios were found between Th1 and Th17 cells in mice treated with various ligands, with the predominance of Th17 observed in mice treated with pertussis toxin or LPS but with more Th1 than Th17 cells identified in the eyes of mice treated with CpG oligodeoxynucleotide (G. Shi, unpublished data).

Analysis of cytokines expressed in the eyes of Th1 and Th17 recipients revealed high levels of selectivity, with a predominance of IFN-γ or IL-17, respectively. Importantly, essentially no IL-17 was detected in Th1 recipient eyes, whereas a low level of IFN-γ was detected in Th17 recipient eyes. The IFN-γ detected in the eyes of Th17 recipients could be produced by three different cell populations: 1) “double positive” cells, producing both IFN-γ and IL-17 (42, 43); 2) Th17 cells that transformed into Th1 cells; and 3) host cells that were recruited into the inflamed eyes (18) and acquired a Th1 phenotype. Data collected in another study (G. Shi, C. A. Cox, B. P. Vistica, C. Tan, E. F. Wawrousek, and I. Gery, “Phenotype switching by inflammation-inducing polarized Th17, but not by Th1 cells,” submitted for publication) suggested that all three mechanisms do in fact take place in Th17 recipient eyes.

Th1 and Th17 differed considerably in their capacity to induce transient splenomegaly as well as an increase in circulating MNLs in naive recipients. The mechanisms involved in these two processes are not entirely known, but it is conceivable that specific cytokines released by adoptively transferred cells played an important role. Differences in cytokine profiles of Th1 and Th17, therefore, may contribute to a difference in the capacity of each cell lineage to induce certain systemic and tissue-specific phenomena. Our notion of Th1-specific spleen enlargement is supported by a recent paper from Uhlig et al. (15), showing that splenomegaly induced by anti-CD40 Ab is IL-12 dependent but relatively unaffected by a deficiency in IL-23.

Flow cytometric analyses of cell populations in enlarged spleens of both Th1 and Th17 recipient mice revealed that the proportions of host CD4 cells, CD8 cells, B cells (CD19+), and dendritic cells (CD11c+) in recipients were similar to those in naive controls. Spleens of both Th1 and Th17 recipients, however, had approximately twice the amount of macrophages (CD11b+) and about three times the amount of granulocytes (Gr-1+) than naive controls (data not shown).

Because Th1 and Th17 were observed to induce different systemic and tissue-specific effects, we analyzed for the expression of cell surface markers known to be involved in activation, maturation, and trafficking. At two stages of in vitro culture, our data indicated that Th1 and Th17 do in fact show remarkable differences in their ability to up-regulate or down-regulate maturation and trafficking markers. At reactivation, the stage just before adoptive transfer, Th17 expressed a more mature effector phenotype than Th1. Furthermore, after a subsequent period of expansion, Th1 and Th17 were found to up-regulate different trafficking markers. Our data show, therefore, that Th1 and Th17 have the ability to express distinct trafficking markers in parallel culture stages, thus offering a potential theory for why Th1 and Th17 differ in their homing patterns to certain types of tissue (15, 44). It is also of note that Nakae et al. recently reported that Th1 and Th17 differ in the expression of various other cell markers (45).

It has been hypothesized that changes in the expression of adhesion markers in vivo enable lymphocytes to leave the circulation and traffic to inflamed tissue (21, 32). This hypothesis is supported by a recent finding that LFA-1 knockout mice do not develop
experimental autoimmune encephalomyelitis, perhaps due to an inability of Th17 to traffic into the CNS (46). We found that Th1 located in recipient spleens postadoptive transfer significantly up-regulated their expression of CXCR3, whereas Th17 up-regulated the integrin αβ2. CXCR3 is a chemokine receptor that has been described to be involved in trafficking to various tissue sites (21, 32, 47), whereas αβ2 is more specialized in trafficking to mucosal tissue (i.e., lamina propria of the gut) (27). In our model of the eye, a major port of entry for inflammatory cells is at the limbus, which comprises mucosal tissue known as conjunctiva-associated lymphoid tissue (48, 49). This observation, therefore, lends support for the role of αβ2 in Th17 trafficking patterns to the eye. Importantly, further analysis of Th17 from the eyes of recipients revealed persistently high αβ2 expression, whereas both Th1 and Th17 significantly down-regulated CXCR3 in the eye.

Furthermore, comparison of Th1 and Th17 surface marker expression at the “reactivated” stage in vitro (Fig. 5) with expression in the recipient eye or spleen (Fig. 6) revealed considerable differences. Of particular interest was the varying expression of two trafficking molecules: 1) αβ2 was more highly expressed by reactivated Th1 in vitro, but Th17 expressed higher levels than Th1 in spleen and eyes; and 2) CXCR3 was nearly absent on reactivated Th1 in vitro but then became highly expressed on Th1 in recipient spleens. These changes in surface marker expression can likely be attributed to different cytokine milieu present in each environment studied.

Interestingly, a drug called natalizumab, which has been used to treat autoimmune diseases such as multiple sclerosis and inflammatory bowel disease (50, 51), is believed to function by blocking the other blocking Abs, such as an antagonist against the whole dimer of the 4 subunit of both CD49d (4/1/H9251 and 4/7/H9252). Furthermore, comparison of Th1 and Th17 surface marker expression at the “reactivated” stage in vitro (Fig. 5) with expression in the recipient eye or spleen (Fig. 6) revealed considerable differences. Of particular interest was the varying expression of two trafficking molecules: 1) αβ2 was more highly expressed by reactivated Th1 in vitro, but Th17 expressed higher levels than Th1 in spleen and eyes; and 2) CXCR3 was nearly absent on reactivated Th1 in vitro but then became highly expressed on Th1 in recipient spleens. These changes in surface marker expression can likely be attributed to different cytokine milieu present in each environment studied.

We thank Drs. Charles E. Egwuagu and Cheng-Rong Yu for useful discussions, and the National Eye Institute Histology Core for preparation of histology slides.

Disclosures
The authors have no financial conflict of interest.

References


